Research Use Only. Not for human or veterinary use.
Nexaflow Research
Vial of lyophilised Retatrutide, 5 mg

Retatrutide

A synthetic peptide agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon receptors.

A subject of published research into incretin and glucagon receptor signalling and metabolic regulation.

Research Use Only. Not for human or veterinary use.

These materials are supplied to laboratories and research organisations as reagents. They are not medicines, are not supplied for administration to humans or animals, and must not be resold for those purposes.

Coming soon — awaiting certificate of analysis confirmation

Not available to order yet. It goes on sale once the certificate for this lot is confirmed; new lots are announced in the weekly email and on Telegram.

Specification

Molecular formula
Not yet specified
Molecular weight
Not yet specified
Sequence
Not yet specified
Purity
≥98% (HPLC)
Appearance
White lyophilised powder
Storage
Store at -20°C, protected from light and moisture.

In the literature

  1. Single or multiple nutritional hormone receptor modulators for chronic kidney disease

    Heerspink HJL · Clinical kidney journal · 2026

    PMID 42959190doi:10.1093/ckj/sfag311

  2. From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease

    Argano C, et al · Frontiers in pharmacology · 2026

    PMID 42947668doi:10.3389/fphar.2026.1784959

  3. Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists

    Bartkowiak D, et al · Cureus · 2026

    PMID 42889249doi:10.7759/cureus.116245

  4. Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective

    Ahmad I, et al · Pharmaceutics · 2026

    PMID 42942813doi:10.3390/pharmaceutics18101281

  5. GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review

    Popa E, et al · International journal of molecular sciences · 2026

    PMID 42883986doi:10.3390/ijms27198738

  6. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence

    Mateescu DM, et al · Pharmaceutics · 2026

    PMID 42942810doi:10.3390/pharmaceutics18101277

  7. Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease-a narrative review with a structured literature search

    Smarkusz-Zarzecka J, et al · Reviews in endocrine & metabolic disorders · 2026

    PMID 42907720doi:10.1007/s11154-026-10098-7

  8. Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile

    Keskin U, et al · Journal of molecular histology · 2026

    PMID 42878930doi:10.1007/s10735-026-11013-9

  9. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide

    Sehgal NKR, et al · JAMA network open · 2026

    PMID 42873503doi:10.1001/jamanetworkopen.2026.38929

  10. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea

    Grunstein RR, et al · The New England journal of medicine · 2026

    PMID 42904878doi:10.1056/NEJMoa2611477

Follow new lots on Telegram

New lot releases, each certificate as it arrives, and restock updates, posted first on Telegram.

Join on Telegram